Healthpeak Properties is showing improving operating momentum across outpatient medical, life science, and senior housing, but valuation remains demanding. The Buy case is supported by stronger same-store NOI, rising occupancy, and a higher full-year FFO outlook.
Healthpeak Properties (DOC) merits a Buy rating for a moderate-risk investor with a medium-term horizon. The thesis rests on three operating levers: outpatient medical leasing, a recovering life science portfolio, and rapidly improving senior housing operations. The company also has a growing capital-recycling platform through partnerships with Brookfield and Blackstone.
The second quarter of 2026 showed tangible progress. Consolidated revenue reached $771.6M, diluted net income was $0.08 per share, and FFO as adjusted was $0.46 per share. Management raised full-year FFO as adjusted guidance to $1.73-$1.77 per share and lifted its same-store cash NOI outlook to 0%-1.5%.
The operating evidence is strongest in outpatient medical and senior housing. Outpatient occupancy rose to 90.7%, cash re-leasing spreads reached 5%, and senior housing delivered 19% NOI growth in the second quarter. Lab occupancy also increased to 78.5%, although that business remains the portfolio's main execution risk.
The main restraint is financial quality. Healthpeak carried $9.3B of debt and $1.6B of cash at June 30, 2026, while annual debt-to-equity stood at 1.3x. Trailing P/E was 54.4x and PEG was 4.1x. Those figures leave limited room for operational disappointment, even though the 10.3% FCF yield and $22.39 analyst consensus target provide support.
Healthpeak Properties is a Denver-based, S&P 500 healthcare REIT incorporated in Maryland in 1985. The company owns, operates, and develops healthcare real estate focused on outpatient medical buildings, life science properties, and senior housing. Healthpeak had 411 employees in the corporate information record.
The company expanded its outpatient medical platform through the March 2024 merger with Physicians Realty Trust. The 2026 10-K states that the merger added 299 outpatient medical buildings and was designed to increase scale, diversification, and investment capacity.
Healthpeak's business model converts specialized real estate into recurring rental income, development returns, asset-management fees, and gains from portfolio recycling. The model is more operationally involved than a simple long-term lease portfolio because senior housing and life science assets require leasing, redevelopment, tenant improvements, and operator relationships.
The company is also shifting from a traditional property owner toward an operating platform. Internalized property management, renewal leasing, development capabilities, and joint ventures with large capital partners give DOC several ways to grow without funding every asset entirely from its own balance sheet.
Outpatient Medical Buildings are the largest segment by 2025 revenue, contributing $1.3B, or 46.5% of the segment total. The portfolio includes 509 properties covering 37M square feet. The investor presentation reported 91% occupancy, 70% health-system tenancy, 96% of assets on or affiliated with hospital campuses, and 5.6 years of remaining lease term.
This segment produced 1.2M square feet of lease executions in the second quarter, including 327,000 square feet of new leasing. Tenant retention was 80%, cash re-leasing spreads were 5%, and occupancy rose 20 basis points sequentially to 90.7%. The combination of rent spreads, 3% escalators, and modest tenant improvements gives outpatient medical the clearest path to steady internal growth.
Lab properties generated $860.0M of 2025 revenue, or 31.4% of the segment total. The portfolio covers 13M square feet in the Bay Area, Boston, and San Diego. Occupancy rose 80 basis points sequentially to 78.5%, up 140 basis points from year-end 2025, while Healthpeak executed 381,000 square feet of leases during the quarter.
Senior Housing contributed $604.0M of 2025 revenue, or 22.1% of the segment total. The portfolio includes 34 communities and 10,422 units across 10 states, with roughly 70% of the portfolio located in Florida and Texas. The operating performance is currently the strongest in the company: same-store occupancy increased 260 basis points and NOI grew 19% in the second quarter.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Healthpeak's flagship product is its integrated outpatient medical platform. This platform combines specialized buildings, health-system relationships, leasing expertise, development capacity, and property management. It is not a single building or service. It is a repeatable operating system for healthcare real estate.
The platform's strongest proof point is the outpatient leasing record. Healthpeak has maintained 5% cash re-leasing spreads over the last 10 quarters, compared with 2%-3% before the Physicians Realty merger. It also completed five development projects with Northside in Atlanta, totaling approximately 565,000 square feet, while holding the No. 1 market share in that market.
The Brookfield transaction further demonstrates the platform's value. Healthpeak retained a 51% interest in a 5.6M-square-foot outpatient portfolio, raised $1.0B of cash proceeds, and retained asset management, property management, leasing, and day-to-day control. The structure converts operating expertise into access to outside equity while preserving tenant relationships.
Janus Living is the second major platform product. Healthpeak owns 74% of the entity, which had approximately $6.5B of equity value in the second-quarter transcript. Janus generated 45% revenue growth and 34% adjusted EBITDA growth, giving DOC a faster-growing operating asset alongside its more stable outpatient portfolio.
Healthpeak's competitive advantage is based on location, tenant relationships, operating expertise, and capital access. Outpatient buildings near hospitals are difficult to replicate in the same location. Life science buildings in San Diego, Boston, and the Bay Area benefit from clustered research activity. Senior housing communities benefit from operating scale and local market knowledge.
The company has also internalized property management and much of its renewal leasing. Management said the Physicians Realty merger produced $70M of realized cost and operating synergies. That combination should reduce dependence on third-party operators and improve control over leasing decisions.
The agentic operating platform mentioned by management is an additional technology initiative. The transcript does not provide a quantified financial contribution, so its value should be judged through future leasing productivity, tenant retention, and operating costs rather than treated as a separate earnings engine today.
Healthpeak's operating chain begins with capital sourcing and property selection, continues through development or acquisition, and ends with tenant leasing, renewals, and asset recycling. The company sources opportunities through hospital relationships, life science clusters, and senior housing operators rather than relying only on broad-market auctions.
Leasing execution remains the critical operating input. Outpatient lease executions reached 2.3M square feet year to date in the second-quarter transcript. Lab activity included 381,000 square feet of quarterly leasing, with approximately 480,000 square feet under letter of intent after July.
Tenant improvement requirements are manageable but vary by property. Management cited approximately 10% of rent for renewals and 20%-25% for new leasing as a long-term rule of thumb. The company also said most available space does not require a shell buildout, which supports faster occupancy and lower capital needs.
Capital recycling is now a central operating tool. Healthpeak generated $1.4B of proceeds in the second quarter and through August 3, bringing year-to-date proceeds to $1.75B. The Brookfield transaction, Janus Living formation, and possible lab acquisitions show how management is moving capital among segments rather than treating the portfolio as static.
The market backdrop supports Healthpeak's outpatient strategy. JLL reported medical outpatient building occupancy of 92.7% in the fourth quarter of 2025, along with 3.3% year-over-year rent growth. That benchmark sits close to DOC's 90.7% outpatient occupancy and supports management's 5% cash re-leasing spreads.
The broader healthcare real estate market was estimated at $1.54T in 2025 and is projected to reach $2.92T by 2033, with an 8.4% CAGR from 2026 through 2033. The U.S. medical office building market is projected to grow at a 6.6% CAGR through 2030, according to the cited market research.
Life science is more cyclical than outpatient medical, but the second-quarter data showed improving conditions. Public biotech capital raising reached its highest level since the second quarter of 2021, 13 later-stage companies raised more than $5B in the first half of 2026, and life science M&A announcements exceeded $250B over the prior three quarters.
Senior housing has a separate demand profile. The U.S. senior living market was estimated at $76.4B in 2026 and is projected to reach $101.9B by 2031. Healthpeak's exposure to Florida and Texas gives Janus Living access to two high-growth markets, though operating results remain more sensitive to labor and occupancy than outpatient medical.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Healthpeak's outpatient customers are primarily health systems, hospitals, physician groups, and ambulatory care providers. Seventy percent of the outpatient portfolio is leased to health systems, and 96% of properties are on or affiliated with hospital campuses. These facts support the view that tenant demand is tied to care delivery rather than discretionary office use.
Life science customers include biotech companies and other research tenants. The leasing pipeline is disproportionately wet lab space, with demand concentrated among biotech tenants seeking core assets and core locations. Tenants in the 25,000-to-75,000-square-foot range represented a growing share of executed leases and letters of intent.
Senior housing customers are residents rather than corporate tenants, which changes the risk profile. Janus Living's 260-basis-point same-store occupancy increase and 19% NOI growth show strong current demand, but staffing, operating costs, and local market execution have a more direct effect on results.
The customer profile gives DOC a useful mix. Health systems provide institutional leasing relationships, biotech tenants provide recovery potential, and senior housing residents provide demographic exposure. The tradeoff is that the portfolio is not equally defensive across all three businesses.
Healthpeak competes with Welltower (WELL), Ventas (VTR), Healthcare Realty Trust (HR), Omega Healthcare Investors (OHI), Sabra Health Care REIT (SBRA), LTC Properties (LTC), National Health Investors (NHI), and Medical Properties Trust (MPW). Alexandria Real Estate Equities (ARE) is a relevant comparison on life science properties.
DOC's portfolio differs from operators focused mainly on skilled nursing or hospitals. Its outpatient medical and life science assets account for most of its operating identity, while senior housing adds a faster-growing but more operationally intensive component. The mix gives DOC exposure to both healthcare delivery and healthcare innovation.
Scale is a meaningful advantage. Healthpeak is an S&P 500 company with 509 outpatient properties, 37M square feet of outpatient space, and 13M square feet of lab space. Its partnerships with Blackstone and Brookfield add capital depth that smaller healthcare REITs may struggle to match.
The competitive weakness is execution complexity. A landlord focused on one property type can optimize leasing and capital spending around one tenant model. Healthpeak must manage outpatient buildings, biotech laboratories, and operating senior housing communities at the same time. That diversification reduces dependence on one market but raises the importance of management discipline.
Interest rates remain the most important macro variable for DOC. Management said the cost of debt was not much lower than the fair market cap rate of the real estate and that elevated leverage was therefore unattractive. The company also closed a $400M unsecured delayed-draw term loan priced at SOFR plus 80 basis points and maturing in March 2031.
Healthcare REIT performance has improved across the sector. Nareit reported a 28.5% total return for healthcare REITs in 2025 and a 23.1% gain through the end of August 2026. That recovery creates a more supportive capital market for DOC, but it also means investors are paying closer attention to asset quality and balance-sheet execution.
The policy-sensitive macro risks are concentrated in healthcare provider economics and senior housing labor costs. Outpatient demand benefits from the shift toward same-day care, while hospital and physician-group financial pressure can slow expansions. Senior housing has stronger current occupancy, but its operating structure exposes DOC to wage and staffing pressures.
No geopolitical event in the supplied record changes the DOC thesis. The relevant external pressures are domestic interest rates, healthcare capital markets, biotech funding, and healthcare operating costs.
Healthpeak carries $9.3B of debt against $1.6B of cash, leaving leverage manageable but not forgiving if execution slips.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revenue reached $771.6M in the second quarter, while FFO as adjusted came in at $0.46 per share and senior housing NOI jumped 19%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted full-year FFO as adjusted guidance to $1.73-$1.77 per share and raised same-store cash NOI expectations to 0%-1.5%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Trailing P/E of 54.4x and PEG of 4.1x leave the stock priced for continued operational improvement despite a 10.3% FCF yield.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s $21 fair value sits above the $18 Buy level and below the $23 Sell level, with analyst consensus at $22.39 providing additional support.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Healthpeak Properties is becoming a more focused healthcare real estate platform. Outpatient medical provides the defensive base, senior housing supplies the fastest current operating growth, and life science offers recovery potential as biotech financing and leasing improve.
The second-quarter results support a constructive medium-term view: revenue reached $771.6M, FFO as adjusted was $0.46 per share, outpatient occupancy reached 90.7%, lab occupancy reached 78.5%, and full-year FFO guidance increased to $1.73-$1.77 per share. The company also demonstrated that its partnerships can produce substantial capital while retaining operating control.
The investment case depends on execution rather than financial engineering. If DOC converts its leasing pipeline, sustains outpatient rent spreads, controls debt, and continues to recycle capital at attractive prices, the $21.00 fair value estimate is achievable. The Buy rating is therefore grounded in improving property fundamentals, with position sizing kept moderate because leverage and lab vacancy remain real constraints.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Healthpeak Properties, Inc. (DOC) gained despite an earnings miss, as revenue beat estimates and operating trends improved across senior housing, lab, and outpatient medical assets. This deep-dive analysis looks beyond the headline to assess occupancy gains, leasing momentum, raised FFO guidance, and what the mixed print means for DOC shares.
Healthpeak Properties, Inc. (DOC) gains 2.4% after reporting earnings misses, as investors weigh the latest results against the stock's recent momentum.
Keith Kohl’s Angel Publishing promotion for Technology and Opportunity, The AI Survivors, names three companies that supposedly can outlast the AI bubble. We test the claim against their filings.